NASDAQ:TTPH - Tetraphase Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.84 -0.01 (-0.54 %) (As of 11/19/2018 04:00 PM ET)Previous Close$1.85Today's Range$1.75 - $1.8552-Week Range$1.75 - $6.97Volume687,249 shsAverage Volume997,039 shsMarket Capitalization$99.21 millionP/E Ratio-0.70Dividend YieldN/ABeta2.67 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with eravacycline through investigating Gram-negative infections treated with eravacycline (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize eravacycline for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts. Receive TTPH News and Ratings via Email Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTPH Previous Symbol CUSIPN/A Webwww.tphase.com Phone617-715-3600 Debt Debt-to-Equity RatioN/A Current Ratio7.28 Quick Ratio7.28 Price-To-Earnings Trailing P/E Ratio-0.70 Forward P/E Ratio-1.30 P/E GrowthN/A Sales & Book Value Annual Sales$9.67 million Price / Sales10.20 Cash FlowN/A Price / CashN/A Book Value$2.53 per share Price / Book0.73 Profitability EPS (Most Recent Fiscal Year)($2.63) Net Income$-114,750,000.00 Net Margins-432.40% Return on Equity-65.89% Return on Assets-57.97% Miscellaneous Employees78 Outstanding Shares53,630,000Market Cap$99.21 million OptionableOptionable Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions What is Tetraphase Pharmaceuticals' stock symbol? Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH." How were Tetraphase Pharmaceuticals' earnings last quarter? Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The biopharmaceutical company had revenue of $1.15 million for the quarter, compared to analyst estimates of $2.09 million. Tetraphase Pharmaceuticals had a negative net margin of 432.40% and a negative return on equity of 65.89%. View Tetraphase Pharmaceuticals' Earnings History. When is Tetraphase Pharmaceuticals' next earnings date? Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Tetraphase Pharmaceuticals. What price target have analysts set for TTPH? 9 brokers have issued 1 year price objectives for Tetraphase Pharmaceuticals' stock. Their predictions range from $3.00 to $10.00. On average, they expect Tetraphase Pharmaceuticals' stock price to reach $6.5714 in the next twelve months. This suggests a possible upside of 257.1% from the stock's current price. View Analyst Price Targets for Tetraphase Pharmaceuticals. What is the consensus analysts' recommendation for Tetraphase Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tetraphase Pharmaceuticals. What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock? Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock: 1. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (10/17/2018) 2. Needham & Company LLC analysts commented, "Tetraphase reported 2Q18 financial results yesterday and we spoke with mgmt for a corporate update. As a reminder, the EMA CHMP issued a positive opinion for Xerava last week. Approval in Europe is likely in Sept or Oct 2018. Xerava is also under review by the FDA, w/ an 8/27/18 PDFUA date. We expect approval. Mgmt has guided for launch in the U.S. in early 4Q18 and in UK and Germany in early 2019. Maintain HOLD, given our concerns over peak sales potential. Although Xerava is an effective antibiotic, we believe the commercial opportunity for new antibiotics in the IV Gram-negative hospital market may be modest." (8/3/2018) 3. HC Wainwright analysts commented, "and Likely Commercial Uptake in cIAI; Affirm Buy Stock Data 05/03/2018 Price $3.15 Exchange NASDAQ Price Target $6.00 52-Week High $8.75 52-Week Low $2.05 Enterprise Value (M) $45.3 Market Cap (M) $163 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 1,678,640 Short Interest (M) 3.41 Shares Outstanding (M): Figure shown is as of May 2, 2018. Balance Sheet Metrics Cash (M) $117.7 Total Debt (M) $0.0 Total Cash/Share $2.28 Book Value/Share $1.93 Cash (M): Figure shown is as of March 31, 2018. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.46) (0.79) (0.42)A 2Q (0.47) (0.83) (0.37) 3Q (0.58) (0.63) (0.31) 4Q (0.61) (0.46) (0.24) FY (2.11) (2.63) (1.32) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 2.0 1.5 1.9A 2Q 1.2 1.6 2.0 3Q 0.9 4.1 1.8 4Q 1.1 2.5 1.5 FY 5.1 9.7 7.2 10 8 6 4 2 0 MAY-17 SEP-17 JAN-18 MAY-18 20 15 10 5 0 Vol. (mil) Price Making it official." (5/4/2018) Has Tetraphase Pharmaceuticals been receiving favorable news coverage? Media coverage about TTPH stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tetraphase Pharmaceuticals earned a news impact score of 0.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. Who are some of Tetraphase Pharmaceuticals' key competitors? Some companies that are related to Tetraphase Pharmaceuticals include Abeona Therapeutics (ABEO), ZEALAND PHARMA/S (ZEAL), Cytokinetics (CYTK), resTORbio (TORC), Zafgen (ZFGN), Stemline Therapeutics (STML), Aclaris Therapeutics (ACRS), American Brivision (Holding) (ABVC), Corbus Pharmaceuticals (CRBP), Verrica Pharmaceuticals (VRCA), Seres Therapeutics (MCRB), Savara (SVRA), TapImmune (MRKR), Minerva Neurosciences (NERV) and Kalvista Pharmaceuticals (KALV). Who are Tetraphase Pharmaceuticals' key executives? Tetraphase Pharmaceuticals' management team includes the folowing people: Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 59)Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 53)Dr. Jacques Dumas, Chief Scientific Officer (Age 52)Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 47)Mr. Larry G. Edwards, Chief Operating Officer (Age 46) Who are Tetraphase Pharmaceuticals' major shareholders? Tetraphase Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.17%), Dimensional Fund Advisors LP (4.76%), Man Group plc (1.67%), Renaissance Technologies LLC (1.65%), Royce & Associates LP (0.90%) and Acadian Asset Management LLC (0.82%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals. Which institutional investors are selling Tetraphase Pharmaceuticals stock? TTPH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, TIAA CREF Investment Management LLC and Gabelli Funds LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals. Which institutional investors are buying Tetraphase Pharmaceuticals stock? TTPH stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Royce & Associates LP, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Canada Pension Plan Investment Board, Man Group plc, BlackRock Inc. and Bridgeway Capital Management Inc.. View Insider Buying and Selling for Tetraphase Pharmaceuticals. How do I buy shares of Tetraphase Pharmaceuticals? Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tetraphase Pharmaceuticals' stock price today? One share of TTPH stock can currently be purchased for approximately $1.84. How big of a company is Tetraphase Pharmaceuticals? Tetraphase Pharmaceuticals has a market capitalization of $99.21 million and generates $9.67 million in revenue each year. The biopharmaceutical company earns $-114,750,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Tetraphase Pharmaceuticals employs 78 workers across the globe. What is Tetraphase Pharmaceuticals' official website? The official website for Tetraphase Pharmaceuticals is http://www.tphase.com. How can I contact Tetraphase Pharmaceuticals? Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected] MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 302 (Vote Outperform)Underperform Votes: 274 (Vote Underperform)Total Votes: 576MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?